Dysregulation of glutamatergic circuits in the brain is involved in the development of centralized chronic pain.
NYX-2925 is in late stage clinical development across two chronic pain indications – Painful Diabetic Peripheral Neuropathy and Fibromyalgia.
Dysregulation of NMDA receptor-mediated processes may underlie the development and / or persistence of PTSD.
NYX-783 is under evaluation in a Phase 2 exploratory study in patients with PTSD.
NMDA receptors are critical to learning and memory processes and their dysregulation has been implicated across numerous conditions involving cognitive impairment.
NYX-458 is under evaluation in a first-in-patient Phase 2 study in cognitive impairment associated with Parkinson’s disease.